Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 14/20 | 0.63 |
| ▸ | HDAC2 | Q92769 | 13/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.40 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10113597 | 0.86 | HDAC1 (0.64) | HDAC1HDAC2CYSLTR2CYSLTR1ALDH1A1 | |
| SCHEMBL13105496 | 0.83 | GRIA1 (0.46) | HDAC1HDAC2CYP1A2HDAC6NPY5R | |
| SCHEMBL10113866 | 0.80 | HDAC1 (0.53) | HDAC1HDAC2LMNAPKMHDAC6 | |
| SCHEMBL10113817 | 0.78 | SMN1; SMN2 (0.45) | LMNA | |
| SCHEMBL10113867 | 0.77 | ALDH1A1 (0.40) | HDAC1HDAC2ALDH1A1LMNAPKM | |
| SCHEMBL933223 | 0.76 | HDAC1 (0.64) | HDAC1HDAC2CYP1A2ALDH1A1LMNA | |
| SCHEMBL10113805 | 0.74 | ALDH1A1 (0.48) | HDAC1ALDH1A1LMNAHDAC6 | |
| SCHEMBL10113790 | 0.73 | HDAC6 (0.74) | HDAC1HDAC2LMNAHDAC6 | |
| SCHEMBL10113860 | 0.72 | LMNA (0.61) | HDAC1HDAC2ALDH1A1LMNAPKM | |
| SCHEMBL20353962 | 0.72 | CYP1A2 (0.61) | HDAC1HDAC2CYP1A2CYSLTR1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8115027-B2 | NPY Y5 antagonist | SHIONOGI & CO., LTD. (JP) | 2012-02-14 | — | — | US | disclosed |
| US-8115027-B2 | NPY Y5 antagonist | SHIONOGI & CO., LTD. (JP) | 2012-02-14 | — | — | US | disclosed |
| US-20110039802-A1 | NPY Y5 ANTAGONIST | KAWANISHI YASUYUKI | 2011-02-17 | — | — | US | disclosed |
| US-20100292500-A1 | NPY Y5 ANTAGONIST | KAWANISHI YASUYUKI | 2010-11-18 | — | — | US | disclosed |
| US-20100292500-A1 | NPY Y5 ANTAGONIST | KAWANISHI YASUYUKI | 2010-11-18 | — | — | US | disclosed |
| US-7781461-B2 | NPY Y5 antagonist | KAWANISHI YASUYUKI | 2010-08-24 | — | — | US | disclosed |
| US-7781461-B2 | NPY Y5 antagonist | KAWANISHI YASUYUKI | 2010-08-24 | — | — | US | disclosed |
| EP-2014285-A1 | NPYY5 antagonists | Shionogi&Co., Ltd. (JP) | 2009-01-14 | — | — | EP | disclosed |
| US-7265130-B2 | NPY Y5 antagonist | SHIONOGI & CO., LTD. (JP) | 2007-09-04 | — | — | US | disclosed |
| US-7265130-B2 | NPY Y5 antagonist | SHIONOGI & CO., LTD. (JP) | 2007-09-04 | — | — | US | disclosed |
| US-20070015762-A1 | NPY Y5 antagonist | KAWANISHI YASUYUKI | 2007-01-18 | — | — | US | disclosed |
| US-20070015762-A1 | NPY Y5 antagonist | KAWANISHI YASUYUKI | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015762-A1 | NPY Y5 antagonist | NPY5R, NPY1R, NPY2R | HDAC1 1995/4885HDAC2 1548/4885CYP1A2 1092/4885 |
| US-20100292500-A1 | NPY Y5 ANTAGONIST | NPY5R, NPY1R, NPY2R | HDAC1 1703/4885HDAC2 1458/4885CYP1A2 1230/4885 |
| US-20110039802-A1 | NPY Y5 ANTAGONIST | NPY5R, NPY1R, NPY2R | HDAC1 2021/4885HDAC2 1524/4885CYP1A2 1051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.